Kooperativer Bibliotheksverbund

UID:

Umfang: 1 online resource (367 pages)

Ausgabe: 1st ed.

ISBN: 9783031335334

Anmerkung: Intro -- Contents -- 1: Rise of the Theranostics Empire: A Commentary on Dr. Baum's Achievements -- 1.1 The Beginning -- 1.2 The Impedance -- 1.3 The Fertilization -- 1.4 Hard Yards -- 1.5 Expansion of the Empire -- 1.6 New Capital -- 2: Review of F-18 FDG PET/CT in Evaluating Response to Immunotherapy Treatment -- 2.1 Introduction -- 2.2 Patterns of Response -- 2.2.1 Pseudoprogression -- 2.2.2 Hyperprogression -- 2.2.3 Durable Response -- 2.3 Mechanism -- 2.4 18FPET CT and irAE -- 2.4.1 Therapy-Related Inflammation and Inverse Relation Liver SUV/Spleen SUV [18] -- 2.5 Conclusion -- References -- 3: Surgery in Combination with Peptide Receptor Radionuclide Therapy: A Novel Approach for the Treatment of Advanced Neuroendocrine Tumours -- 3.1 Introduction -- 3.2 Molecular Imaging of Neuroendocrine Neoplasms -- 3.3 Surgical Treatment -- 3.4 Surgery in Combination with Peptide Receptor Radionuclide Therapy -- 3.5 Conclusions -- References -- 4: From Concept to Clinic and Commercialization: Cowboys Wanted -- 4.1 Professor Richard Baum -- 4.2 The Great Bexxar® Disaster -- 4.3 "Us Versus Them" -- 4.4 Intellectual Property: Who Cares? -- 4.5 Imaging Is Not an Easy Business -- 4.6 Entrepreneurs Beware -- 4.7 Build It and They Will Come -- 4.8 A Fragile Supply Chain -- 4.9 Future Frontiers -- 4.10 Concluding Remarks -- References -- 5: From Radiochemistry of the Lanthanides to 225Ac and the Interference with Richard Baum -- 5.1 Personal Introduction -- 5.2 Situation of Nuclear Medicine in the 60-th -- 5.3 How to Make Sort-lived Nuclides Far from Beta Stability -- 5.4 Optimized Extraction Chromatography -- 5.5 Separations Based on Szilard-Chalmers Effect -- 5.6 High-temperature Release Studies of Radio-lanthanides from Refractory Metals -- 5.7 ISOLDE and the On-line Production Lanthanide Nuclides. , 5.8 Isotopes in Medicine: Situation in the 60-th -- 5.9 Metallic Positron Emitters -- 5.10 The Alpha Emitters 149Tb and 225Ac -- 5.11 From "Radioactive Ion Beams for Bio-Medical Research" Until CERN Medicis: A New Facility -- 5.12 The 225Ac Story -- 5.13 Where the 225Ac Comes From -- 5.14 Summarizing -- References -- 6: "How Do You Feel About Dosimetry?" The Gretchenfrage of Radionuclide Therapy -- 6.1 The Gretchenfrage -- 6.2 The Forms of Dosimetry in a Nutshell -- 6.3 Dose Quantities and Dose-Response in EBRT -- 6.4 Dose-Response I: Radiotoxicities in Radionuclide Therapy -- 6.5 Dose-Response II: Tumor Response in Radionuclide Therapy -- 6.6 The Answer to the Gretchenfrage -- References -- 7: The LuGenIum Triptych: Ode to a Theranostic Transcriptome -- 7.1 Retrospective Analysis of Toxicity -- 7.2 Circulating NET Transcripts -- 7.3 Circulating NET Transcripts and SSR Imaging -- 7.4 Circulating NET Transcripts and PRRT -- 7.5 Validation Study of PRRT Genomic Signature in Blood (PPQ) for the Prediction of 177Lu-octreotate Efficacy -- 7.6 Validation Study of Multigene NET-Specific Circulating Transcript Signature for the Monitoring of 177Lu-octreotate Efficacy -- 7.7 Future Developments -- References -- 8: A Tree Can Be Recognized by Its Fruit -- 8.1 Introduction -- 8.2 Fruits of Scientist Baum -- 8.3 Fruits of Doctor Baum -- 8.3.1 Fruits of Our Friend Baum -- References -- 9: IAEA Strategy for Enhancing the Sustainability of Nuclear Medicine in Low- and Middle-Income Countries -- 9.1 Introduction -- 9.2 Key Challenges -- 9.3 Interventions -- 9.4 Results -- 9.4.1 Technical Cooperation Programme -- 9.4.2 Quality Assurance -- 9.4.3 Procurement -- 9.4.4 Education -- 9.4.5 Coordinated Research Activities -- 9.5 Conclusion -- References -- 10: Radionuclide Therapy in Brain Tumours -- 10.1 Introduction. , 10.1.1 Radionuclides Used in the Therapy -- 10.1.1.1 Alpha-Emitter Radionuclide -- 10.1.1.2 Beta-Emitter Radionuclide -- 10.1.2 Routes of Drug Administration -- 10.1.2.1 Systemic Administration of Radioconjugates -- 10.1.2.2 Locoregional Application of Radioconjugates -- 10.2 Peptide Receptor Radionuclide Therapy -- 10.2.1 Biologic Targets for PRRT -- 10.2.1.1 Neurokinin Type 1 Receptor -- 10.2.1.2 Glioma Chloride Channels -- 10.2.1.3 Somatostatin Receptor -- 10.2.2 Clinical Studies -- 10.3 Immune-Based Radionuclide Therapy -- 10.3.1 Biologic Targets for RIT -- 10.3.1.1 Tenascin-C -- 10.3.1.2 Epidermal Growth Factor Receptor -- 10.3.1.3 Neural Cell Adhesion Molecule -- 10.3.1.4 Histone H1 -- 10.3.2 Future Novel Targets -- 10.3.2.1 Fibulin-3 -- 10.3.3 Clinical Studies -- 10.3.4 Challenges and Future Directions -- 10.3.4.1 Challenges -- 10.3.4.2 The Blood-Brain Barrier (BBB) -- 10.3.4.3 Tumoral Heterogeneity -- 10.3.5 Conclusion -- References -- 11: Modern Diagnostic and Therapeutic Approaches in Thyroid Diseases: Theranostics and the Changing Role of Radioactive Isotopes -- 11.1 Conclusion -- References -- 12: Cardiotoxicity of Targeted Therapies: Imaging of Heart Does Matter -- 12.1 Cancer Targeted Therapies -- 12.2 Cardiotoxicity of Cancer Targeted Therapy -- 12.3 Diagnostic Tools to Detect Myocardial Toxicity -- 12.3.1 Anamnesis and Risk Stratification -- 12.3.2 Electrocardiography -- 12.3.3 Cardiac Biomarkers -- 12.3.4 Imaging Modalities for Cardiotoxicity Screening -- 12.3.4.1 Echocardiography -- 12.3.4.2 Cardiac Magnetic Resonance -- 12.3.4.3 Nuclear Positron Emission Tomography -- 12.3.4.4 Conventional Nuclear Imaging -- 12.3.4.5 Cardiac Computed Tomography, Angio-Coronary Computer Tomography -- 12.4 Summary -- References. , 13: The Evolution of n.c.a. 177Lu to n.c.a. 177Lu-Edotreotide for the Treatment of Neuroendocrine Tumours. Sixteen Years of Collaboration Between Zentralklinik Bad Berka and ITM -- 13.1 Introduction -- 13.2 No-Carrier-Added Lutetium-177: The Gold Standard for Radionuclide Treatment -- 13.3 No-Carrier-Added Lutetium-177-Edotreotide for Treatment of Neuroendocrine Tumours -- 13.4 Conclusion and Acknowledgements -- References -- 14: Fighting for PET in German Oncological Guidelines and for Its Reimbursement by Statutory Health Insurances -- References -- 15: Precision Oncology with PSMA-Targeted α-Particle Therapy of mCRPC -- 15.1 Introduction -- 15.2 Prostate-Specific Membrane Antigen as Biological Target -- 15.3 PSMA PET -- 15.4 PSMA β-Particle Radioligand Therapy -- 15.5 PSMA α-Particle Radioligand Therapy -- 15.5.1 Actinium-225 -- 15.5.2 Bismuth-213 -- 15.5.3 Thorium-227 -- 15.5.4 Lead-212 -- 15.5.5 Terbium-149 -- 15.6 Summary -- References -- 16: From Radioimmunodetection to Radiomolecular Precision Oncology Via Radionanotargeting by Intelligent Multidisciplinary Radiotheragnostic Nanoparticles -- References -- 17: Nuclear Medicine and Surgery on the Way to Personalized Medicine. Ten Years of Clinical and Translational Oncology and Research -- References -- 18: PSMA Radioligand Therapy: A Revolution in the Precision Radiomolecular Oncology of Prostate Cancer -- References -- 19: The Role of Individuals for Innovation: The Nuclear Medicine Biotope -- References -- 20: Working at Isotopentherapiestation D3: A Daily Challenge or Adventure Never Stops -- 21: Theranostics in Australia: The Importance of Vision and Training, and the Power of Collaboration -- References -- 22: Theranostic Radiopeptides in Nuclear Oncology: Design, Preclinical Screening, and Clinical Translation -- 22.1 Introduction. , 22.2 Peptides and GPCR Targets on Tumors -- 22.3 Radiometals and Their Chelators in Cancer Theranostics -- 22.4 Metabolic Stability of Radiopeptides: The Pep-Protect Concept -- 22.5 Radiopeptide Agonists and Antagonists -- 22.6 Radiopeptide Candidates for Clinical Translation -- References -- 23: Terbium "Sisters": More Than just a "Swiss Army Knife" -- 23.1 Introduction -- 23.2 The PET Sister: Terbium-152 -- 23.3 The SPECT Sister: Terbium-155 -- 23.4 The Alpha Therapy Sister: Terbium-149 -- 23.5 The Beta TherapyPLUS Sister (βτ̔̈ΑΕ·/Conversion/Auger-e)̄: Terbium-161 -- 23.6 Conclusion and Outlook -- References -- 24: High-Performance Radiopharmacy: The Base for Precision Oncology -- References -- 25: Analyzing the Science Footprint of Richard P. Baum -- 25.1 Introduction -- 25.2 Material and Methods -- 25.3 Results -- 25.4 Discussion -- 25.5 Conclusion -- References -- 26: Therapy of Castration-Resistant Prostate Cancer: Where Is the Place of 225Ac-PSMA? -- 26.1 Introduction -- 26.2 177Lu-PSMA Versus 225Ac-PSMA PRT in mCRPC -- 26.3 Efficacy of 225Ac-PSMA as a Last-Line Therapy of mCRPC -- 26.4 Toxicities of 225Ac-PSMA for PRLT of mCRPC -- 26.5 Upfront Application of 225Ac-PSMA for Therapy of mCRPC in Chemotherapy-Naïve Patients -- 26.6 Conclusion and Future Perspectives -- References -- 27: Sola Dosis Facit Venenum: Dosimetry for Molecular Radiotherapy in Bad Berka -- 27.1 Introduction -- 27.2 Bad Berka Dose Protocol -- 27.3 Dosimetry in Daily Clinical Routine -- 27.4 Dosimetry for PRRT -- 27.5 PRRT Antagonists -- 27.6 Dosimetry for PSMA Radioligand Therapy -- 27.7 Conclusions -- References -- 28: On the Use of 203Pb Imaging to Inform 212Pb Dosimetry for 203/212Pb Image-Guided Alpha-Particle Therapy for Cancer -- 28.1 Introduction -- 28.2 203Pb SPECT/CT Imaging in Advance of 212Pb α-RT. , 28.3 Prediction of 212Pb Dosimetry Based on 203Pb Imaging.

Weitere Ausg.: Print version: Prasad, Vikas Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum Cham : Springer International Publishing AG,c2024 ISBN 9783031335327

Sprache: Englisch

Schlagwort(e): Electronic books. ; Festschrift ; Festschrift ; Festschrift ; Festschrift

URL: Click to View

URL: lizenzpflichtig

URL: Volltext  (kostenfrei)

URL: Volltext  (kostenfrei)

URL: Volltext  (kostenfrei)

URL: Volltext  (kostenfrei)

URL: Volltext  (kostenfrei)

URL: Volltext  (kostenfrei)

URL: kostenfrei

URL: Volltext  (kostenfrei)

URL: Volltext  (kostenfrei)

UID:

Umfang: 1 online resource (367 pages)

Ausgabe: 1st ed. 2024.

ISBN: 3-031-33533-3

Inhalt: This open access book is written by world-renowned experts on radiomolecular precision oncology to celebrate the work, life, principles and ideology of Richard P. Baum. It includes commentaries, reviews and some thought provoking novel ideas on radionuclide precision oncology, covering topics such as various aspects of theranostics and molecular radiotherapy like radiolabeled peptides, radiolabeled antibodies, dosimetry, and quality control as well as the diagnosis and treatment of specific tumor types. Featuring contributions by biologists, physicists, chemists, mathematicians, geneticists, and physicians from a range of specialties, this Festschrift is highly interdisciplinary and will be a valuable resource for future precision oncologists. .

Anmerkung: 1. The Rise of A Theranostic Empire: Good Governance and Precision Oncology -- 2. 18 FDG PET CT assessing Inmunotherapy response -- 3. Radionuclide Therapy in Brain Tumours -- 4. From Concept to Clinic and Comercialisation - Cowboys Wanted -- 5. From Radiochemistry of the Lanthanides to 225Ac and the interference with Richard Baum -- 6. How do you feel about dosimetry?" The Gretchenfrage of Radionuclide Therapy -- 7. The LuGenIum Triptych Ode to a Theranostic Transcriptome -- 8. A tree can be recognized by its fruit -- 9. IAEA Strategy for Enhancing the Sustainability of Nuclear Medicine in Low- and Middle- Income Countries -- 10. Combining surgery with peptide receptor radionuclide therapy – a step forward in treatment of advanced neuroendocrine tumours -- 11. Modern diagnostic and therapeutic approaches in thyroid diseases - Theranostics and the changing role of radioactive isotopes – -- 12. Cardiotoxicity of targeted therapies: Imaging of Heart Does Matter -- 13. Following the co-evolution of Innovation and demand in the field of precision oncology -- 14. Fighting for PET in German oncological guidelines and for its reimbursement by Statutory Health Insurances -- 15. Precision Oncology with PSMA-targeted Alpha Particle Therapy of mCRPC -- 16. From Radioimmunodetection to Radiomolecular Precision Oncology via Radionanotargeting by Intelligent Multidisciplinary Radiotheragnostic Nanoparticles -- 17. Nuclear medicine and surgery a new productive new marriage -- 18. 'PSMA Radioligand Therapy - A Revolution in the Precision Oncology of Prostate Cancer' -- 19. The Role of Individuals for Innovation: The Nuclear Medicine Biotope -- 20. Working at ISOTOPENTHERAPIESTATION D3- a daily challenge or adventure never stops -- 21. Combining targeted radiation therapies in modern clinical oncological practice -- 22. Theranostic Radiopeptides in Nuclear Oncology: Design, Preclinical Screening & Clinical Translation -- 23. Terbium “Sisters”: More than just a “Swiss Army Knife” -- 24. High-Performance Radiopharmacy - The Base for Precision Oncology -- 25. Analyzing the science footprint of Richard P. Baum -- 26. Ac-225 PSMA in metastatic prostate cancer without previous chemotherapy -- 27. 'Sola dosis facit venenum: Dosimetrie in Precision Oncology with Radiolabelled Probe' -- 28. theranostic pair 203Pb and 212Pb for image-guided alpha/beta particle therapy for cancer. -- 29. Radioiodine labeled metaiodobenzylguanidine for imaging and treatment of the adrenal medulla and extra-adrenal paraganglia tumors -- 30. A (188)Re-juvenatiNG JOURNEY WITH HERCULES -- 31. CXCR4 Theranostic Experience from India -- 32. Can VPAC Targeted Cu-67-TP3805 Play a Theranostic Role for Prostate Cancer?: A Quest -- 33. REAL-WORLD EVIDENCE: CLINICAL OUTCOMES IN PRECISION RADIONUCLIDE ONCOLOGY. The WARMTH NIGHTCAP Study of 177Lu-PSMA in Metastatic Prostate Cancer. -- 34. Uptake of 68Ga-DOTATATE and 68Ga-DOTATOC in primary neuroendocrine tumors, metastases, and normal liver tissue – isthere a significant difference? -- 35. Theranostics with somatostatin receptor antagonists. -- 36. Molecular in-vitro & in-vivo diagnostics as the impartible basis of multimodal therapy approaches in precision oncology -- 37. Molecular imaging platform and radio-pharmaceutical transnational research on Peking University Cancer Hospital -- 38. Dose it possible to targeting HER2 using Affibody receptor radionuclide therapy.

Weitere Ausg.: Print version: Prasad, Vikas Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum Cham : Springer International Publishing AG,c2024 ISBN 9783031335327

Sprache: Englisch

DOI: 10.1007/978-3-031-33533-4

UID:

Umfang: 1 online resource (367 p.)

ISBN: 9783031335334 , 3031335333

Anmerkung: Description based upon print version of record. , 7.5 Validation Study of PRRT Genomic Signature in Blood (PPQ) for the Prediction of 177Lu-octreotate Efficacy , Intro -- Contents -- 1: Rise of the Theranostics Empire: A Commentary on Dr. Baum's Achievements -- 1.1 The Beginning -- 1.2 The Impedance -- 1.3 The Fertilization -- 1.4 Hard Yards -- 1.5 Expansion of the Empire -- 1.6 New Capital -- 2: Review of F-18 FDG PET/CT in Evaluating Response to Immunotherapy Treatment -- 2.1 Introduction -- 2.2 Patterns of Response -- 2.2.1 Pseudoprogression -- 2.2.2 Hyperprogression -- 2.2.3 Durable Response -- 2.3 Mechanism -- 2.4 18FPET CT and irAE -- 2.4.1 Therapy-Related Inflammation and Inverse Relation Liver SUV/Spleen SUV [18] , 2.5 Conclusion -- References -- 3: Surgery in Combination with Peptide Receptor Radionuclide Therapy: A Novel Approach for the Treatment of Advanced Neuroendocrine Tumours -- 3.1 Introduction -- 3.2 Molecular Imaging of Neuroendocrine Neoplasms -- 3.3 Surgical Treatment -- 3.4 Surgery in Combination with Peptide Receptor Radionuclide Therapy -- 3.5 Conclusions -- References -- 4: From Concept to Clinic and Commercialization: Cowboys Wanted -- 4.1 Professor Richard Baum -- 4.2 The Great Bexxar® Disaster -- 4.3 "Us Versus Them" -- 4.4 Intellectual Property: Who Cares? , 4.5 Imaging Is Not an Easy Business -- 4.6 Entrepreneurs Beware -- 4.7 Build It and They Will Come -- 4.8 A Fragile Supply Chain -- 4.9 Future Frontiers -- 4.10 Concluding Remarks -- References -- 5: From Radiochemistry of the Lanthanides to 225Ac and the Interference with Richard Baum -- 5.1 Personal Introduction -- 5.2 Situation of Nuclear Medicine in the 60-th -- 5.3 How to Make Sort-lived Nuclides Far from Beta Stability -- 5.4 Optimized Extraction Chromatography -- 5.5 Separations Based on Szilard-Chalmers Effect , 5.6 High-temperature Release Studies of Radio-lanthanides from Refractory Metals -- 5.7 ISOLDE and the On-line Production Lanthanide Nuclides -- 5.8 Isotopes in Medicine: Situation in the 60-th -- 5.9 Metallic Positron Emitters -- 5.10 The Alpha Emitters 149Tb and 225Ac -- 5.11 From "Radioactive Ion Beams for Bio-Medical Research" Until CERN Medicis: A New Facility -- 5.12 The 225Ac Story -- 5.13 Where the 225Ac Comes From -- 5.14 Summarizing -- References -- 6: "How Do You Feel About Dosimetry?" The Gretchenfrage of Radionuclide Therapy -- 6.1 The Gretchenfrage , 6.2 The Forms of Dosimetry in a Nutshell -- 6.3 Dose Quantities and Dose-Response in EBRT -- 6.4 Dose-Response I: Radiotoxicities in Radionuclide Therapy -- 6.5 Dose-Response II: Tumor Response in Radionuclide Therapy -- 6.6 The Answer to the Gretchenfrage -- References -- 7: The LuGenIum Triptych: Ode to a Theranostic Transcriptome -- 7.1 Retrospective Analysis of Toxicity -- 7.2 Circulating NET Transcripts -- 7.3 Circulating NET Transcripts and SSR Imaging -- 7.4 Circulating NET Transcripts and PRRT

Weitere Ausg.: Print version: Prasad, Vikas Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum Cham : Springer International Publishing AG,c2024 ISBN 9783031335327

Sprache: Englisch

Schlagwort(e): Electronic books.

URL: Click here to view book

UID:

Umfang: VIII, 380 p. 143 illus., 120 illus. in color. , online resource.

Ausgabe: 1st ed. 2024.

ISBN: 9783031335334

Inhalt: This open access book is written by world-renowned experts on radiomolecular precision oncology to celebrate the work, life, principles and ideology of Richard P. Baum. It includes commentaries, reviews and some thought provoking novel ideas on radionuclide precision oncology, covering topics such as various aspects of theranostics and molecular radiotherapy like radiolabeled peptides, radiolabeled antibodies, dosimetry, and quality control as well as the diagnosis and treatment of specific tumor types. Featuring contributions by biologists, physicists, chemists, mathematicians, geneticists, and physicians from a range of specialties, this Festschrift is highly interdisciplinary and will be a valuable resource for future precision oncologists. .

Anmerkung: 1. The Rise of A Theranostic Empire: Good Governance and Precision Oncology -- 2. 18 FDG PET CT assessing Inmunotherapy response -- 3. Radionuclide Therapy in Brain Tumours -- 4. From Concept to Clinic and Comercialisation - Cowboys Wanted -- 5. From Radiochemistry of the Lanthanides to 225Ac and the interference with Richard Baum -- 6. How do you feel about dosimetry?" The Gretchenfrage of Radionuclide Therapy -- 7. The LuGenIum Triptych Ode to a Theranostic Transcriptome -- 8. A tree can be recognized by its fruit -- 9. IAEA Strategy for Enhancing the Sustainability of Nuclear Medicine in Low- and Middle- Income Countries -- 10. Combining surgery with peptide receptor radionuclide therapy - a step forward in treatment of advanced neuroendocrine tumours -- 11. Modern diagnostic and therapeutic approaches in thyroid diseases - Theranostics and the changing role of radioactive isotopes - -- 12. Cardiotoxicity of targeted therapies: Imaging of Heart Does Matter -- 13. Following the co-evolution of Innovation and demand in the field of precision oncology -- 14. Fighting for PET in German oncological guidelines and for its reimbursement by Statutory Health Insurances -- 15. Precision Oncology with PSMA-targeted Alpha Particle Therapy of mCRPC -- 16. From Radioimmunodetection to Radiomolecular Precision Oncology via Radionanotargeting by Intelligent Multidisciplinary Radiotheragnostic Nanoparticles -- 17. Nuclear medicine and surgery a new productive new marriage -- 18. 'PSMA Radioligand Therapy - A Revolution in the Precision Oncology of Prostate Cancer' -- 19. The Role of Individuals for Innovation: The Nuclear Medicine Biotope -- 20. Working at ISOTOPENTHERAPIESTATION D3- a daily challenge or adventure never stops -- 21. Combining targeted radiation therapies in modern clinical oncological practice -- 22. Theranostic Radiopeptides in Nuclear Oncology: Design, Preclinical Screening & Clinical Translation -- 23. Terbium "Sisters": More than just a "Swiss Army Knife" -- 24. High-Performance Radiopharmacy - The Base for Precision Oncology -- 25. Analyzing the science footprint of Richard P. Baum -- 26. Ac-225 PSMA in metastatic prostate cancer without previous chemotherapy -- 27. 'Sola dosis facit venenum: Dosimetrie in Precision Oncology with Radiolabelled Probe' -- 28. theranostic pair 203Pb and 212Pb for image-guided alpha/beta particle therapy for cancer. -- 29. Radioiodine labeled metaiodobenzylguanidine for imaging and treatment of the adrenal medulla and extra-adrenal paraganglia tumors -- 30. A (188)Re-juvenatiNG JOURNEY WITH HERCULES -- 31. CXCR4 Theranostic Experience from India -- 32. Can VPAC Targeted Cu-67-TP3805 Play a Theranostic Role for Prostate Cancer?: A Quest -- 33. REAL-WORLD EVIDENCE: CLINICAL OUTCOMES IN PRECISION RADIONUCLIDE ONCOLOGY. The WARMTH NIGHTCAP Study of 177Lu-PSMA in Metastatic Prostate Cancer. -- 34. Uptake of 68Ga-DOTATATE and 68Ga-DOTATOC in primary neuroendocrine tumors, metastases, and normal liver tissue - is there a significant difference? -- 35. Theranostics with somatostatin receptor antagonists. -- 36. Molecular in-vitro & in-vivo diagnostics as the impartible basis of multimodal therapy approaches in precision oncology -- 37. Molecular imaging platform and radio-pharmaceutical transnational research on Peking University Cancer Hospital -- 38. Dose it possible to targeting HER2 using Affibody receptor radionuclide therapy.

In: Springer Nature eBook

Weitere Ausg.: Printed edition: ISBN 9783031335327

Weitere Ausg.: Printed edition: ISBN 9783031335341

Weitere Ausg.: Printed edition: ISBN 9783031335358

Sprache: Englisch

DOI: 10.1007/978-3-031-33533-4

URL: https://doi.org/10.1007/978-3-031-33533-4